Trial Profile
A Phase Ib, Open-Label, Dose-Escalation Study Of The Safety, Tolerability, and Pharmacokinetics of Cobimetinib and GDC-0994 In Patients With Locally Advanced or Metastatic Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Jul 2021
Price :
$35
*
At a glance
- Drugs Cobimetinib (Primary) ; Ravoxertinib (Primary)
- Indications Adenocarcinoma; Appendiceal cancer; Colorectal cancer; Lung cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genentech
- 05 Apr 2017 Results assessing safety and tolerability, pharmacokinetics and preliminary efficacy, presented at the 108th Annual Meeting of the American Association for Cancer Research
- 05 Apr 2017 Status changed from active, no longer recruiting to completed.
- 01 Jun 2016 Status changed from recruiting to active, no longer recruiting.